» Articles » PMID: 25364036

Paraneoplastic Neurological Syndrome in Fallopian Tube Cancer

Overview
Date 2014 Nov 4
PMID 25364036
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

We report on a rare case of paraneoplastic syndrome (PS) that was discovered on completion of diagnostic work-up to be an undifferentiated fallopian tube carcinoma. A 49-year-old Caucasian woman was admitted to neurology with vertigo, gait ataxia and dysarthria, transient ischaemic attack (TIA) and stroke were quickly excluded. Indicative for the further diagnosis of a paraneoplastic syndrome was the identification of onconeuronal antibodies the detection of which can be associated with certain tumour entities. The strongly positive anti-Yo antibody that is formed above all by breast and lung cancers as well as ovarian cancer led to a corresponding staging. The tumour markers CEA, CA 125 and CA 15-3 were in the normal ranges. Mammography and thorax CT were also unremarkable; on transvaginal sonography the internal genitals were inconspicuous except for a follicular cyst on the left. On abdominal CT the only conspicuous finding was a 1.5 cm ovarian cyst. After consensual agreement a bilateral laparoscopic adenexectomy was performed but with unremarkable abdominal findings. The histological examination confirmed a right-sided undifferentiated tubal carcinoma with the provisional classification FIGO IIA. After a stage-related staging operation, the final classification was found to be the FIGO-IIIC stage on account of positive retroperitoneal lymph nodes. Thus adjuvant chemotherapy with 6 cycles of carboplatin and paclitaxel was performed. By means of a timely, guideline-conform therapy for tubal carcinoma, the neurological symptoms and, above all, the dysarthria could be improved after 10 months.

Citing Articles

Paraneoplastic encephalitis with leukoencephalopathy in primary fallopian tube carcinoma.

Shinagawa A, Barrera N, Taylor M, Dragicevic N Radiol Case Rep. 2020; 15(7):904-907.

PMID: 32395191 PMC: 7203515. DOI: 10.1016/j.radcr.2020.04.013.

References
1.
Darnell J, Albert M, Darnell R . Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res. 2000; 60(8):2136-9. View

2.
David Y, Warner E, Levitan M, Sutton D, Malkin M, Dalmau J . Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. Cancer. 1996; 78(10):2153-6. View

3.
Vergote I, Trope C, Amant F, Kristensen G, Ehlen T, Johnson N . Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363(10):943-53. DOI: 10.1056/NEJMoa0908806. View

4.
Caliandro P, Luigetti M, Ricci E, Mirabella M, Tonali P, Padua L . Cerebellar degeneration and ocular myasthenia gravis in a patient with recurring ovarian carcinoma. Neurol Sci. 2009; 31(1):79-81. DOI: 10.1007/s10072-009-0154-3. View

5.
Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G . Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010; 67(3):330-5. DOI: 10.1001/archneurol.2009.341. View